Semaglutide did more than cut weight in this analysis of 6,239 adults
A meta-analysis of more than 6,000 adults reveals how semaglutide affects weight and key metabolic markers, while new…
Atorvastatin reduces major cardiovascular events but misses disability-free survival goal
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but…
Daily multivitamin improves functional health in older adults, study finds
The ability to perform everyday activities free of debilitating symptoms profoundly affects quality of life as we age.…
Fish oil supplementation during pregnancy changes two childhood brain metabolic markers
A decade after mothers received EPA- and DHA-rich fish oil, MRI scans revealed subtle metabolic differences in their…
Can ibuprofen improve drug-resistant tuberculosis treatment?
Could a common over-the-counter anti-inflammatory drug become a new weapon against drug-resistant tuberculosis? Early findings suggest immune benefits,…
Common drug shows promise in preventing post-surgical liver failure
A multi-center study, co-led by researchers at Mayo Clinic and Michigan State University, found that patients who received tranexamic acid during…
Tezepelumab reduces steroid dependence in severe asthma patients
New results from the Phase 3 SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term…
Ocrelizumab slows disability progression in advanced progressive multiple sclerosis
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab…
Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression
Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University…
Scientists identify methylphenidate as an effective tool for combating chronic cancer related fatigue
A new meta-analysis in the May 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network provides updated…
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus…
Obesity drugs and surgery linked to greater fat-free mass loss
A new systematic review and meta-analysis of studies presented at this year’s European Congress on Obesity in Istanbul,…